Patients with HER2-positive metastatic breast cancer may consider related side effects and quality of life outcomes when choosing treatments.

In presenting Dr Slamon with the Ulysses Medal, UCD recognises that his pursuit of novel therapies for breast cancer for over ...

Per Genentech, the current price of Herceptin for a patient with “HER2 positive metastatic breast cancer” as about $50,000, a ...

A 22-year-old LASU student is urgently seeking N15 million financial assistance as she battles an aggressive form of breast ...

Following its initial approval at 150 mg, trastuzumab-strf has also been approved at 420 mg for the treatment of several HER2 ...

Accord BioPharma, the speciality division of Intas Pharmaceuticals, has received US Food and Drug Administration (FDA) ...

The Food and Drug Administration (FDA) has approved a 420mg dosage strength of Hercessi ™ (trastuzumab-strf), a biosimilar to Herceptin ® (trastuzumab). Hercessi, a HER2/neu receptor antagonist, is ...

In a 10-year analysis of the ShortHER trial, high tumor-infiltrating lymphocytes were associated with improved survival in ...

Using Herceptin as an example, Andre Ilbawi detailed the challenges low- and medium-income countries face in accessing essential therapies.

Monoclonal antibodies – treatments developed by cloning a cell that makes an antibody – could help provide an answer to the ...

Jazz Pharmaceuticals has posted fresh phase 2 data on zanidatamab that show the HER2-targeted bispecific antibody kept 59% of ...

Ann Marie Rogers won a landmark victory to make the breast cancer drug Herceptin more widely available. Here, she explains what drove her. But others are asking if the treatment really lives up to ...